Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | USP14 | P54578 | 6/20 | 0.40 |
| ▸ | USP7 | Q93009 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2866851 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1HPGDLMNAAKR1C3 | |
| SCHEMBL2865204 | 0.85 | USP14 (0.41) | ALDH1A1HPGDAKR1C3USP14GFER | |
| SCHEMBL2865201 | 0.85 | USP14 (0.41) | ALDH1A1HPGDAKR1C3USP14GFER | |
| SCHEMBL2863241 | 0.84 | HPGD (0.42) | ALDH1A1HPGDLMNAAKR1C3CNR1 | |
| SCHEMBL2863238 | 0.84 | HPGD (0.42) | ALDH1A1HPGDLMNAAKR1C3CNR1 | |
| SCHEMBL2869615 | 0.78 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1HPGDLMNAUSP14 | |
| SCHEMBL2869617 | 0.78 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1HPGDLMNAUSP14 | |
| SCHEMBL2863033 | 0.78 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1HPGDLMNAAKR1C3 | |
| SCHEMBL2863036 | 0.78 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1HPGDLMNAAKR1C3 | |
| SCHEMBL2865350 | 0.77 | HPGD (0.43) | SMN1; SMN2ALDH1A1HPGDLMNAAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245020-B1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-01-15 | — | — | EP | claimed |
| US-8383657-B2 | Thiazolylidine urea and amide derivatives and methods of use thereof | ABBOTT LABORATORIES (US) | 2013-02-26 | — | — | US | claimed |
| EP-2245020-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2010-11-03 | — | — | EP | claimed |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-09-03 | — | — | US | claimed |
| WO-2009086163-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | WO | claimed |
| WO-2009082698-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-07-02 | — | — | WO | claimed |
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | claimed |
| EP-2245020-B1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8383657-B2 | Thiazolylidine urea and amide derivatives and methods of use thereof | ABBOTT LABORATORIES (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2245020-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2009086163-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009082698-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | NMUR1, NMUR2, PAM | SMN1; SMN2 1424/4885ALDH1A1 2649/4885HPGD 827/4885 |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | CHRNA4, CHRNA5, CHRNA3 | SMN1; SMN2 2490/4885ALDH1A1 2032/4885HPGD 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.